180,632 deferred stock units granted to Iovance (IOVA) director Dukes

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS director Iain D. Dukes received a grant of 180,632 deferred restricted stock units (DRSUs) linked to the company’s common stock. The award was made at no cash exercise price under the company’s 2018 Equity Incentive Plan.

The DRSUs vest if Dukes continues providing service until the earlier of the first anniversary of the grant date or the day before the next annual shareholder meeting. Actual common shares are issued later, upon specified events such as board departure, a qualifying change in control, or ten years after the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dukes Iain D.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Deferred Restricted Stock Unit	180,632	$0.00	--

Holdings After Transaction: Deferred Restricted Stock Unit — 180,632 shares (Direct, null)

Footnotes (1)

Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Key Figures

DRSUs granted: 180,632 units Grant price: $0.00 per unit DRSUs held after grant: 180,632 units +1 more

4 metrics

DRSUs granted 180,632 units Deferred restricted stock units awarded on June 16, 2026

Grant price $0.00 per unit Stated transaction price for DRSU grant

DRSUs held after grant 180,632 units Total deferred restricted stock units following this transaction

Underlying common stock 180,632 shares Common shares underlying the DRSUs

Key Terms

Deferred Restricted Stock Unit, 2018 Equity Incentive Plan, change in control, vesting

4 terms

Deferred Restricted Stock Unit financial

"Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share"

2018 Equity Incentive Plan financial

"are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended)"

change in control financial

"a change in control (as defined in the DRSU agreement)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vesting financial

"the DRSUs shall vest on the earlier of: (i) the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 05:17 PM Accepted by SEC EDGAR 06/18/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dukes Iain D.

(Last)

(First)

(Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS

CALIFORNIA

94070

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Restricted Stock Unit	⁽¹⁾	06/16/2026		A		180,632		⁽²⁾	⁽²⁾	Common Stock	180,632	$0	180,632	D

Explanation of Responses:

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

	/s/ Iain Dukes	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did IOVANCE BIOTHERAPEUTICS (IOVA) disclose in this Form 4 for Iain D. Dukes?

IOVANCE BIOTHERAPEUTICS reported that director Iain D. Dukes received 180,632 deferred restricted stock units. Each unit represents a right to one common share, granted under the 2018 Equity Incentive Plan, as part of his equity-based board compensation.

How many deferred restricted stock units did IOVANCE (IOVA) grant to director Iain D. Dukes?

Iovance granted Iain D. Dukes 180,632 deferred restricted stock units. These units are tied to the company’s common stock and were awarded with a stated price of $0.00 per unit under the company’s 2018 Equity Incentive Plan.

When do IOVANCE (IOVA) deferred restricted stock units for Iain D. Dukes vest?

The DRSUs for Iain D. Dukes vest if he continues service until the earlier of the first anniversary of the grant date or the day before Iovance’s next annual shareholder meeting, according to the award’s vesting terms described in the filing footnotes.

When will IOVANCE (IOVA) common shares from these DRSUs be delivered to Iain D. Dukes?

Common shares underlying the DRSUs will be issued to Iain D. Dukes at the earlier of three months after his board service ends, a qualifying change in control, his death or disability, or ten years from the grant date, per the award’s deferral terms.

What plan governs IOVANCE (IOVA) director Iain D. Dukes’ deferred restricted stock units?

The deferred restricted stock units granted to Iain D. Dukes are issued under Iovance’s 2018 Equity Incentive Plan, as amended. This plan authorizes equity-based awards, including DRSUs that settle in common stock upon specified vesting and distribution events.